Skip to main content

Advertisement

SpringerLink
Log in

Challenges in conducting clinical research studies in pregnant women

  • Review Paper
  • Published:
Journal of Pharmacokinetics and Pharmacodynamics Aims and scope Submit manuscript

Abstract

Maternal mortality and morbidity continue to rise in the United States. Despite these trends there are limited novel interventions to investigate and improve these metrics, partly due to research protocol limitations which restrict participation of pregnant women. Inclusion of pregnant women in research studies is integral to the process of obtaining important information regarding the safety and efficacy of therapeutics or interventions to improve maternal health and pregnancy outcomes. While significant changes in research practices have resulted in an increase of female participants, there remains a paucity of research trials directly targeting pregnant and lactating women. This article provides an overview of issues surrounding inclusion of pregnant or breastfeeding women in research studies, and includes historical perspectives, navigating concerns over safety profile, considerations for appropriate development, and future perspectives.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Gonzalez D, Boggess KA, Cohen-Wolkowiez M (2015) Lessons learned in pediatric clinical research to evaluate safe and effective use of drugs in pregnancy. Obstet Gynecol 125(4):953–958

    Article  CAS  Google Scholar 

  2. Illamola SM, Bucci-Rechtweg C, Costantine MM, Tsilou E, Sherwin CM, Zajicek A (2018) Inclusion of pregnant and breastfeeding women in research: efforts and initiatives. Br J Clin Pharmacol 84(2):215–222

    Article  Google Scholar 

  3. Gynecologists ACoOa (2015) Ethical considerations for including women as research participants. Committee Opinion No. 646. Obstet Gynaecol. 126:e100–107

  4. Shanks N, Greek R, Greek J (2009) Are animal models predictive for humans? Philos Ethics Humanit Med 4:2

    Article  Google Scholar 

  5. Hoover RN, Hyer M, Pfeiffer RM et al (2011) Adverse health outcomes in women exposed in utero to diethylstilbestrol. N Engl J Med 365(14):1304–1314

    Article  CAS  Google Scholar 

  6. Vargesson N (2015) Thalidomide-induced teratogenesis: history and mechanisms. Birth Defects Res C Embryo Today 105(2):140–156

    Article  CAS  Google Scholar 

  7. Food US, Drug A (1993) Guideline for the study and evaluation of gender differences in the clinical evaluation of drugs; notice. Fed Regist 58(139):39406–39416

    Google Scholar 

  8. Food and Drug Administration (1979) Labeling and prescription drug advertising: content and format for labeling for human prescription drugs. Fed Reg 44:37434–37467

    Google Scholar 

  9. Prescription drug products; patient labeling requirements proposed rule. Fed Regist 44(131 Pt 2):40015–40041

  10. Doering PL, Boothby LA, Cheok M (2002) Review of pregnancy labeling of prescription drugs: is the current system adequate to inform of risks? Am J Obstet Gynecol 187(2):333–339

    Article  Google Scholar 

  11. National Institutes of Health Revitalization Act 1993; Science and Technology. Vol. Public Law, pp. 103–143

  12. Cleary KL, Roney K, Costantine M (2014) Challenges of studying drugs in pregnancy for off-label indications: pravastatin for preeclampsia prevention. Semin Perinatol 38(8):523–527

    Article  Google Scholar 

  13. Administration USFaD (2006) Requirements on content and format of labeling for human prescription drug and biological products Proposed rule. Fed Regist 2006(71):3921–3997

    Google Scholar 

  14. Content and Format of Labeling for Human Prescription Drug and Biological Products; Requirements for Pregnancy and Lactation Labeling. Fed Regist.233:72064–72103.

  15. Ayad M, Costantine MM (2015) Epidemiology of medications use in pregnancy. Semin Perinatol 39(7):508–511

    Article  Google Scholar 

  16. McCormack SA, Best BM (2014) Obstetric pharmacokinetic dosing studies are urgently needed. Front Pediatr 2:9

    Article  Google Scholar 

  17. Regulation (EU) No 536/2014 of the European Parliament and of the Council of 16 April 2014 on clinical trials on medicinal products for human use arD.

  18. Saint-Raymond A, de Vries CS (2016) Medicine safety in pregnancy and ambitions for the EU medicine regulatory framework. Clin Pharmacol Ther 100(1):21–23

    Article  CAS  Google Scholar 

  19. Lupattelli A, Spigset O, Twigg MJ et al (2014) Medication use in pregnancy: a cross-sectional, multinational web-based study. BMJ Open 4(2):e004365

    Article  CAS  Google Scholar 

  20. Mitchell AA, Gilboa SM, Werler MM et al (2011) Medication use during pregnancy, with particular focus on prescription drugs: 1976–2008. Am J Obstet Gynecol. 205(1):51

    Article  Google Scholar 

  21. Glover DD, Amonkar M, Rybeck BF, Tracy TS (2003) Prescription, over-the-counter, and herbal medicine use in a rural, obstetric population. Am J Obstet Gynecol 188(4):1039–1045

    Article  Google Scholar 

  22. Centers for Disease Controls & Prevention. Use of Medication in Pregnancy. 2016. https://www.cdc.gov/pregnancy/meds/treatingfortwo/data.html.

  23. Adam MP, Polifka JE, Friedman JM (2011) Evolving knowledge of the teratogenicity of medications in human pregnancy. Am J Med Genet C Semin Med Genet 157C(3):175–182

    Article  Google Scholar 

  24. Mazer-Amirshahi M, Samiee-Zafarghandy S, Gray G, van den Anker JN (2014) Trends in pregnancy labeling and data quality for US-approved pharmaceuticals. Am J Obstet Gynecol. 211(6):690

    Article  Google Scholar 

  25. Marwick C (1997) Thalidomide back–under strict control. JAMA 278(14):1135–1137

    Article  CAS  Google Scholar 

  26. Sheffield JS, Siegel D, Mirochnick M et al (2014) Designing drug trials: considerations for pregnant women. Clin Infect Dis 59(Suppl 7):S437–444

    Article  CAS  Google Scholar 

  27. Schwenzer KJ (2008) Protecting vulnerable subjects in clinical research: children, pregnant women, prisoners, and employees. Respir Care 53(10):1342–1349

    PubMed  Google Scholar 

  28. Zimmerman K, Gonzalez D, Swamy GK, Cohen-Wolkowiez M (2015) Pharmacologic studies in vulnerable populations: using the pediatric experience. Semin Perinatol 39(7):532–536

    Article  Google Scholar 

  29. Costantine MM, Cleary K, Hebert MF et al (2016) Safety and pharmacokinetics of pravastatin used for the prevention of preeclampsia in high-risk pregnant women: a pilot randomized controlled trial. Am J Obstet Gynecol. 214(6):720

    Article  CAS  Google Scholar 

  30. Dallmann A, Mian P, Van den Anker J, Allegaert K (2019) Clinical pharmacokinetic studies in pregnant women and the relevance of pharmacometric tools. Curr Pharm Des 25(5):483–495

    Article  CAS  Google Scholar 

  31. PRGLAC Report to HHS Secretary and Congress. Eunice Kennedy Shriver National Institute of Child Health and Human Development. https://www.nichd.nih.gov/sites/default/files/2018-09/PRGLAC_Report.pdf (accessed March 20, 2020).

  32. List of Recommendations from the Task Force on Research Specific to Pregnant Woman and Lactating Women. Eunice Kennedy Shriver National Institute of Child Health and Human Development. https://www.nichd.nih.gov/about/advisory/PRGLAC/recommendations. Accessed 20 March 2020.

  33. U.S. Department of Health and Human Services PHS, National Institutes of Health, Office of Research on Women’s Health. Bethesda, MD: National Institutes of Health. Enrolling Pregnant Women: Issues in Clinical Research. 2011.

  34. Costantine MM, Cleary K, Eunice Kennedy Shriver National Institute of Child H, Human Development Obstetric-Fetal Pharmacology Research Units N (2013) Pravastatin for the prevention of preeclampsia in high-risk pregnant women. Obstet Gynecol 121:349–353

    Article  CAS  Google Scholar 

  35. American College of O, Gynecologists, the Society for Maternal-Fetal M, Kilpatrick SK, Ecker JL (2016) Severe maternal morbidity: screening and review. Am J Obstet Gynecol 215(3):17–22

  36. Marrs CC, Costantine MM (2017) Should we add pravastatin to aspirin for preeclampsia prevention in high-risk women? Clin Obstet Gynecol 60(1):161–168

    Article  Google Scholar 

  37. Edison RJ, Muenke M (2004) Mechanistic and epidemiologic considerations in the evaluation of adverse birth outcomes following gestational exposure to statins. Am J Med Genet A 131(3):287–298

    Article  Google Scholar 

  38. Kazmin A, Garcia-Bournissen F, Koren G (2007) Risks of statin use during pregnancy: a systematic review. J Obstet Gynaecol Can 29(11):906–908

    Article  Google Scholar 

  39. Ofori B, Rey E, Berard A (2007) Risk of congenital anomalies in pregnant users of statin drugs. Br J Clin Pharmacol 64(4):496–509

    Article  Google Scholar 

  40. Taguchi N, Rubin ET, Hosokawa A et al (2008) Prenatal exposure to HMG-CoA reductase inhibitors: effects on fetal and neonatal outcomes. Reprod Toxicol 26(2):175–177

    Article  CAS  Google Scholar 

  41. Bateman BT, Hernandez-Diaz S, Fischer MA et al (2015) Statins and congenital malformations: cohort study. BMJ 350:h1035

    Article  Google Scholar 

  42. Brownfoot FC, Tong S, Hannan NJ et al (2015) Effects of Pravastatin on human placenta, endothelium, and women with severe preeclampsia. Hypertension 66(3):687–697

    Article  CAS  Google Scholar 

  43. Kumasawa K, Ikawa M, Kidoya H et al (2011) Pravastatin induces placental growth factor (PGF) and ameliorates preeclampsia in a mouse model. Proc Natl Acad Sci U S A 108(4):1451–1455

    Article  Google Scholar 

  44. Pfeffer MA, Keech A, Sacks FM et al (2002) Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) Project. Circulation 105(20):2341–2346

    Article  CAS  Google Scholar 

  45. Nanovskaya TN, Patrikeeva SL, Paul J, Costantine MM, Hankins GD, Ahmed MS (2013) Transplacental transfer and distribution of pravastatin. Am J Obstet Gynecol. 209(4):373–375

    Article  CAS  Google Scholar 

  46. Zarek J, DeGorter MK, Lubetsky A et al (2013) The transfer of pravastatin in the dually perfused human placenta. Placenta 34(8):719–721

    Article  CAS  Google Scholar 

  47. Carver AR, Tamayo E, Perez-Polo JR, Saade GR, Hankins GD, Costantine MM (2014) The effect of maternal pravastatin therapy on adverse sensorimotor outcomes of the offspring in a murine model of preeclampsia. Int J Dev Neurosci 33:33–40

    Article  CAS  Google Scholar 

  48. Carver AR, Andrikopoulou M, Lei J et al (2014) Maternal pravastatin prevents altered fetal brain development in a preeclamptic CD-1 mouse model. PLoS ONE 9(6):e100873

    Article  Google Scholar 

  49. McDonnold M, Tamayo E, Kechichian T et al (2014) The effect of prenatal pravastatin treatment on altered fetal programming of postnatal growth and metabolic function in a preeclampsia-like murine model. Am J Obstet Gynecol 210(6):542.e541–547

    Article  CAS  Google Scholar 

  50. Lefkou E, Mamopoulos A, Dagklis T, Vosnakis C, Rousso D, Girardi G (2016) Pravastatin improves pregnancy outcomes in obstetric antiphospholipid syndrome refractory to antithrombotic therapy. J Clin Invest 126(8):2933–2940

    Article  Google Scholar 

Download references

Acknowledgements

MMC is supported by a grant from The Eunice Kennedy Shriver National Institute of Child Health and Human Development (5 UG1 HD027915-29) and the National Heart, Lung, and blood institute (1UG3HL140131-01). This commentary does not necessarily represent the official views of the NICHD, NHLBI, or the National Institute of Health.

Author information

Authors and Affiliations

  1. Division of Maternal Fetal Medicine, Department Obstetrics & Gynecology, The Ohio State University Wexner Medical Center, 395 W12th Avenue, Columbus, OH, 43210, USA

    Monique McKiever, Heather Frey & Maged M. Costantine

Authors
  1. Monique McKiever
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Heather Frey
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Maged M. Costantine
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Maged M. Costantine.

Ethics declarations

Conflict of interest

None of the authors have any conflicts to disclose

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

McKiever, M., Frey, H. & Costantine, M.M. Challenges in conducting clinical research studies in pregnant women. J Pharmacokinet Pharmacodyn 47, 287–293 (2020). https://doi.org/10.1007/s10928-020-09687-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10928-020-09687-z

Keywords

Search

Navigation